Tags

59 recent news items

  1. Stanford launches a five-year Digital Brain Project

    Stanford’s Wu Tsai Neurosciences Institute has launched a five-year project to build predictive computational models of the human brain. Researchers will collect complementary brain-imaging and behavioral datasets using 7-Tesla MRI and wearable OPM-MEG, then train foundation models to study brain function and disease. The project plans to make its datasets and models freely available to researchers worldwide; these are planned outputs, not a completed model release.

  2. Flagship Pioneering forms Etcelera by merging Cellarity, Etiome and Empress Therapeutics platforms (AI causal-biology drug discovery)

    Flagship Pioneering announced on 29 October 2026 the formation of Etcelera, created by merging the platforms of Cellarity, Etiome and Empress Therapeutics with Flagship's in-house AI. Ad Rawcliffe leads it. The platform combines human transcriptomic data, chemoproteomics and perturbation data, including a foundation model trained on 150 million cells and 30+ AI prediction models, with programs in hematology, metabolism (MASH) and immunology. Cellarity's sickle cell program CLY-124 moves to a standalone company. AI-for-science/biotech news; no phage angle found (Empress works on small molecules from commensal-bacteria metabolites).

  3. Insilico Medicine launches DDDBench Core, a live leaderboard of 59 drug-discovery benchmarks

    DDDBench Core is a live leaderboard of 59 drug discovery and development benchmarks, selected from 302 in Insilico Medicine's Foundations set, comparing generalist frontier models with Insilico's compact specialist MMAI models; the page lists GPT 6 Astra (medium) first with a Core score of 52.5. Announced on X on 27 October 2026. Company-run benchmark on which its own models are ranked.

  4. Pythia Labs launches with Pythia-1, AI-designed full-length antibodies against hard targets

    Pythia Labs announced its launch on October 27, 2026 alongside a bioRxiv preprint introducing Pythia-1, an all-atom generative model that designed full-length human IgGs across 22 targets, including GPCR agonist and antagonist antibodies. The company shares the lead antibody sequences; results are the company's own and weights or code are not stated. Business Wire release.

  5. Anthropic reports six drug-development partnerships and starts its own discovery programs

    Anthropic reports that over several months its scientists have worked with six organizations developing new medicines (BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group) and have begun drug discovery efforts of their own, with technical reports on the case studies. The results are Anthropic's and its partners' own; the post is dated October 27, 2026.

  6. Divergence Labs reports Claude-designed antibody parts that remove receptor-bound IgE (food allergy)

    Divergence Labs published a preprint with Anthropic describing an agentic design campaign with Claude toward a biparatopic antibody that physically removes IgE bound to its receptor FcεRI, as a food-allergy therapy candidate. Of 91 experimentally characterized disruptor designs, 20 were active against receptor-bound IgE and three variants removed more IgE than omalizumab at 25-400 nM; de novo anchor arms bound IgE with apparent affinities of 3.4-235 nM. The two arms are not yet assembled and no cell or animal data are reported; the results are the company's own, early and preclinical. Announced 27 October 2026.

  7. Seven years of Pittsburgh Phage Program data presented at IDWeek 2026: 357 requests, 77 approved single-patient applications

    Healio reports (October 26, 2026) on the Pittsburgh Phage Program's seven-year review presented by Ghady Haidar at IDWeek 2026 (Washington, October 21-24). From November 2019 to April 2026 the program received 357 phage requests, 347 of which produced an isolate for screening; phages were identified for 246. Of 77 approved single-patient applications, 73 patients received or were pursuing therapy. Day-28 outcomes were adjudicated for 26 patients (41% improved, 36% stable); the researchers reported no deaths attributable to phages and urged a move from compassionate use to clinical trials. Figures are as reported by Healio; the IDWeek abstract was not found.

  8. Xaira introduces X-Automate, pairing a robotic arm with its X-Scientist agent to run lab instruments autonomously

    Xaira Therapeutics introduced X-Automate, which combines X-Bot, an in-house vision-guided six-degree-of-freedom robotic arm, with the X-Scientist agent to move plates between instruments. In a seven-day HPLC demonstration the system autonomously retrieved, transported and analyzed 18 plates, 80 percent more than a modeled weekday 9-to-5 loading schedule (company-reported). Announced 23 October 2026, two days after X-Scientist.

  9. PNNL begins building an autonomous microbial research laboratory

    PNNL has broken ground on the Microbial Molecular Phenotyping Capability, an expansion of its Environmental Molecular Sciences Laboratory planned to open in 2029. More than 100 connected instruments will automate microbial growth, sample preparation and analysis to link observable traits with cellular mechanisms. PNNL says researchers at universities, industry and national laboratories across the United States will be able to seek no-cost access through EMSL’s competitive proposal process once the facility opens.

  10. OpenAI, PerturbAI and Scripps Research use thousands of GPT-Rosalind agents on brain CRISPR data

    OpenAI reports that, with PerturbAI and Scripps Research, thousands of AI agents powered by GPT-Rosalind analysed existing experimental data from millions of mouse brain cells in 32 minutes, linking gene-disruption effects to the literature to surface leads on Alzheimer's and Parkinson's biology (post dated October 21, 2026). The leads are hypotheses from the authors' own analysis.

  11. CNRS reviews France’s phage-therapy research and public production proposals

    CNRS surveys how French researchers are developing phage therapy, from matching phages to individual infections and producing pharmaceutical-quality preparations to proposing a network of public manufacturing capacity. The article includes clinical, social-science and agricultural perspectives, and stresses that evidence of effectiveness for specific infections remains limited. Public infrastructure is presented as a proposal, not an established national service.